PortViewPortView
Savara logo

Savara (SVRA) Stock Analysis

NASDAQHealthcareBiotechnology

$5.43+1.50%
1-year price historyRange $3.37 – $6.94
52-week range$5.43
$3.32$7.01

What Savara does

Savara Inc. is a biopharmaceutical firm in the clinical development phase, specializing in therapies for uncommon respiratory conditions. Their primary investigational drug, molgramostim, is an inhaled form of granulocyte-macrophage colony-stimulating factor (GM-CSF). This compound is currently undergoing Phase III trials to address autoimmune pulmonary alveolar proteinosis. The company's main operations are situated in Austin, Texas.

Key metrics

Market cap
$1.11B
P/E (TTM)
-9.70
EPS (TTM)
$-0.56
Beta
0.26
Dividend yield
0.00%
Revenue / share
$0.00
50-day avg
$5.68
200-day avg
$5.57
52-week high
$7.01
52-week low
$3.32
CEO
Matthew Pauls

ETFs linked to SVRA

Broad-market and Healthcare sector ETFs an investor holding Savara is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how SVRA fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Analyze SVRA in PortView →

Similar companies

Frequently asked questions

What is the ticker symbol for Savara?
Savara trades under the ticker SVRA on NASDAQ.
Which exchange is SVRA listed on?
SVRA is listed on NASDAQ.
What sector does Savara operate in?
Savara is classified in the Healthcare sector (Biotechnology industry).
How can PortView help analyze SVRA in a portfolio?
PortView shows SVRA's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.